Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
Hyejee Ohm(University of Alberta), Naveen S. Basappa, Simon Tanguay(McGill University Health Centre), Rodney H. Breau(University of Ottawa), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Frédéric Pouliot(Université Laval), Bimal Bhindi, Nazanin Fallah‐Rad(Princess Margaret Cancer Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Antonio Finelli(University Health Network), Mehul Gupta, Dominick Bossé(Dana-Farber Cancer Institute), Daniel Yick Chin Heng(University of Calgary), Jeffrey Graham(University of Calgary)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
|The Journal of Urology|2020|268